tivantinib + docetaxel

**Tivantinib + docetaxel** is an investigational combination therapy where tivantinib, a **non-ATP competitive inhibitor of c-MET receptor tyrosine kinase** (also with additional cytotoxic mechanisms such as tubulin inhibition), is combined with docetaxel, a cytotoxic taxane that stabilizes microtubules and inhibits cell division. Tivantinib inhibits c-MET, a receptor often overexpressed in several cancers, notably non-small cell lung cancer (NSCLC) and castration-resistant prostate cancer, while docetaxel impedes microtubule depolymerization, promoting cell death in rapidly dividing cells. This combination is investigated primarily for advanced solid tumors (notably prostate and lung cancers), aiming to exploit potential synergy between the c-MET inhibition (targeted therapy) and traditional cytotoxic chemotherapy[2][3].